drugset / Trial / NCT07496749

KD Treatment for Super-refractory Status Epilepticus

NCT07496749 ↗

Recruiting 84 enrolled Xuanwu Hospital, Beijing
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate to evaluate the efficacy and safety of ketogenic diet (KD) as an adjunctive therapy in patients with Super Refractory Status Epilepticus (SRSE) in the intensive care unit (ICU).

Timeline

Start
2025-10-20
Primary completion
2027-02-01
Completion
2027-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Midazolam Small molecule 0.1 mg/kg Intravenous
Background Midazolam Small molecule 0.6 mg/kg Intravenous

Indications